Friday, November 23, 2012

Singapore - Microfluidic Chip Maker Wins Big At The Asian Innovation Awards

Singapore-based Clearbridge BioMedics has won three awards at The Asian Innovation Awards 2012.

Singapore-based Clearbridge BioMedics has won three awards at The Asian Innovation Awards 2012. The results were announced on Tuesday in Hong Kong.

The Awards are presented annually by The Wall Street Journal in partnership with Credit Suisse.
Clearbridge BioMedics took home the grand prize for The Asian Innovation Awards 2012, which recognizes innovations that improve quality of life or productivity. It also received the Credit Suisse Technopreneur of the Year Award, which honors technologies with the greatest potential for commercial success.

It beat out 11 other finalists who had been shortlisted from more than 240 applications.
As a bonus, it also won the Audience Choice Award, which was based on the votes of the audience at the event.

“Innovation and entrepreneurship play essential roles in driving economic growth across the Asia-Pacific region. My congratulations to Clearbridge BioMedics on their ingenuity and success in this year’s Asian Innovation Awards,” said Mr. Dan Molloy, global executive director for multimedia sales, Asia, for The Wall Street Journal.

Clearbridge BioMedics began as a spin-off company from the Faculty of Engineering at the National University of Singapore.

It is commercializing its proprietary ClearCell™ System to detect, isolate, and retrieve wholly-intact circulating tumor cells (CTCs) from small quantities of patient blood samples. The ClearCell™ System has achieved ISO13485 certification, and is available for the cancer research market.

“Clearbridge BioMedics is absolutely delighted and honored to win, not one but three awards, at the Asian Innovation Awards. We aim to further develop our ClearCell™ System into a health-care solution that will empower cancer clinicians and researchers to manage cancer in a more effective manner,” said Mr. Johnson Chen, Founder of Clearbridge BioMedics.

No comments:

Post a Comment